- Report
- January 2021
- 600 Pages
United States
From €2690EUR$2,800USD£2,313GBP
- Report
- November 2020
- 124 Pages
Global
From €1153EUR$1,200USD£991GBP
- Report
- August 2022
- 119 Pages
Global
From €4324EUR$4,500USD£3,718GBP
From €2498EUR$2,600USD£2,148GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9609EUR$10,000USD£8,262GBP
- Report
- July 2023
- 123 Pages
China
From €1730EUR$1,800USD£1,487GBP
- Report
- April 2023
- 129 Pages
Global
€4804EUR$5,000USD£4,131GBP
- Report
- January 2024
- 93 Pages
Global
From €3500EUR$3,902USD£3,115GBP
- Report
- July 2023
- 244 Pages
China
From €3843EUR$4,000USD£3,305GBP
Goserelin is a drug used in the treatment of breast cancer. It is a synthetic form of the hormone gonadotropin-releasing hormone (GnRH) and is used to reduce the production of estrogen in the body. Goserelin is typically used in combination with other drugs to treat breast cancer, such as tamoxifen or an aromatase inhibitor. It is also used to reduce the risk of recurrence in women who have already been treated for breast cancer.
Goserelin is available in both injectable and implantable forms. The injectable form is administered every four weeks, while the implantable form is inserted under the skin and slowly releases the drug over a period of time.
Goserelin is manufactured by several pharmaceutical companies, including Novartis, Pfizer, and Sanofi. It is available in many countries around the world, including the United States, Canada, and the United Kingdom. Show Less Read more
